echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Finance Express . . . In July 2020, the national medical and health industry financing summary.

    Finance Express . . . In July 2020, the national medical and health industry financing summary.

    • Last Update: 2020-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    90 financing cases, disclosed amount of about 13.116 billion yuan, billion yuan and above financing cases 22, the amount and amount of financing in the B-round stage before, from the quantity and amount of investment bias.
    the top three sub-sectors of the total number of financing projects: medical devices, pharmaceuticals, medical services;
    projects are concentrated in Beijing, Shanghai, Jiangsu, Guangdong and Zhejiang, with a total of about 87% of the total financing projects.
    July financing profile 1. Number and scale In July, the domestic medical and health industry first-level market financing 90, the amount disclosed is about 13.116 billion yuan, the financing amount of more than 100 million yuan in 22 cases, the total disclosed financing amount of about 12.67 billion yuan, the total amount of financing of more than 100 million yuan accounted for 96.6% of the total financing scale in the current month.
    disclosed this month that the largest financing was a $2.08 billion equity financing from the new drug developer, Baiji Shenzhou, including Gaoji Capital, Baker Brothers and Amgen.
    is also the largest equity offering by a biotech company in the history of biopharmaceuticals worldwide.
    This month's second largest financing project is: innovative drug developer Haihe Pharmaceuticals completed 1.2 billion yuan B round of financing, led by Huaping Investment, China Merchants International, Junlian Capital, COFCO Capital, Chaos Investment, Langzi Hana, Boyuan Capital, PCCW Capital, United Ventures, Shi pharmaceutical group, Ruihua Investment and Shanghai Science and Technology Venture Fund.
    will be used to accelerate the development and launch of several of the company's new anti-tumor drugs worldwide.
    the third largest financing project this month was completed by Cancer and Immunological Diseases Drug Developers" and Platinum Pharmaceuticals, a $102.8 million round of C financing led by Hudson Bay Capital, with the participation of Obo Capital, Bigelow Ventures, Gottja Investment Group, Octagon Investments, Reeve Capital and existing investors, The Bay Area Common Home Development Fund. Table
    July Health Industry Financing Scale TOP10 Project 2. Financing Phase Distribution July, the number of domestic health industry financing projects concentrated in the A-round stage (including angel wheel, seed wheel, Pre-A round, A-plus round), a total of 35, accounting for 38.9%;
    Figure 1 In July, the number of financing projects in the medical device sector was 22, accounting for 24.4% of the total number of financing projects, the largest number of financing projects in this month, followed by the pharmaceutical research and development sector, which accounted for 23.3%, and the medical services sector, which accounted for 7.8%.
    2 Distribution of the amount of financing in the sub-sectors from the scale of financing, the pharmaceutical sector is the most fund-absorbing sub-sectors, the total amount of disclosed financing as high as 11.19 billion yuan.
    the medical device sector, with a total disclosure of about $485 million.
    third is the industrial services sector, with a total disclosed financing of 470 million yuan.
    3 Distribution of financing amounts in sub-sectors 1. The largest amount in the pharmaceutical sector this month came from a $2.08 billion equity raising in Baiji Shenzhou.
    's research and development team has provided clinically 11 self-developed drugs over the past decade, two of which have been approved for market and the third is about to be declared on the market.
    to this day, there are nearly 30 new anti-tumor drugs in the early pipeline of Baiji Shenzhou, eight of which have global benefits and ten of which are phase III clinical trials worldwide.
    Oncology drug developer Deki Pharmaceuticals received a $97 million round of C financing led by Fidelity Management and Research Company LLC, with other new investors including Gao Wei Ventures, GIC and a large well-known long-term institutional investor, with existing investors including Qiming Ventures and Boyu Capital continuing to participate.
    this round of financing will be mainly used for the development and commercialization of new drugs.
    $80 million round of financing for the clinically proven drug developer of rare diseases, "Yu Pharmaceuticals".
    The current round of financing is led by Quancheng Capital, a Chinese healthcare investment agency, Sanzheng Health Investment and Shuanghu Capital, and continues to make additional investments by three founding investment institutions, Staus Capital, F-Prime Capital and Viking Capital.
    2 July partial financing in the pharmaceutical sector 2. Medical device breast cancer screening equipment manufacturer "Frame Guande Core" completed 150 million yuan B-plus round of financing, managed by CCB International Jianxing Medical Fund, seven wolf venture capital and investment.
    previously, Mr. Frame view had received several rounds of investment from CHINA Capital, IDG, Northern Lights, National Science Investment and other institutions.
    funds will be used to fully start the production base construction and mass production of products such as surface photon counting mammography machines and dental in-mouth imaging systems, and to promote the development of photon counting products such as synchritis radiation detectors, DSA, CT, etc.
    medical device product developer "Aico Medical" completed the super-billion yuan B round of financing, led by Sequoia Capital China Fund, Huagai Capital and Investment.
    Ike Medical is a full product line company in the field of neural intervention, developing and manufacturing medical device products for the treatment of aneurysms, prevention and treatment of bleeding diseases caused by rupture of angiotherms, which are Class III passive implantable medical devices.
    , Ike Medical has completed innovative designs for several products.
    Micro-invention medical device manufacturer "Bomai Medical" access to hundreds of millions of yuan C round of financing, high-rise venture capital lead investment, Kaihui Fund and service trade fund with investment, old shareholder Northern Lights venture capital and investment, Hao Yue Capital as the current round of financing of the exclusive financial adviser.
    this round of financing will be used to further promote the company's product development and marketing and expansion of production. Table
    3 Overview of the geographical distribution of financing for medical device financing in July, with financing projects concentrated in Shanghai, Jiangsu, Guangdong, Beijing and Zhejiang (87%) respectively, of which Beijing accounted for 21.1%, Shanghai for 20%, Jiangsu for 16.7%, Guangdong for 15.6%, Zhejiang for 13.3%, and Hubei for 2 financing projects, Shandong, Hebei, Guangxi, Hunan, Xinjiang and Fujian.
    the amount of financing, the most gold-sucking city this month was Beijing, with a total of 7.07 billion yuan.
    followed by Shanghai and Jiangsu at 2,654 million yuan and 1.46 billion yuan, respectively.
    Tu: In July, the number and amount of financing disclosed nationwide 1. Lu Daopei Medical Group, a professional medical institution in Beijing, completed more than RMB500 million in round B equity financing, which was led by Singapore's sovereign fund Temasek and invested by Investcorp.
    pharmaceutical e-commerce platform "Drug Pocket Network" completed nearly 100 million yuan B round of financing, the current round of financing is mainly led by Shen Wanhongyuan Capital Investment, Nanyi Ventures and old shareholders with investment.
    the completion of this round of financing, the drug network extends downstream of the industry, further extending and improving the industrial chain through the layout of new pharmaceutical retail business and Internet hospitals.
    "Rossum Robot", a supplier of medical robotics, completed a 10 million yuan Pre-A round of financing, led by Jinke Jun Ventures, Inspiring Star, Zhiyou Jinmiao and Investment.
    this round of financing will be used to advance the company's intelligent orthopaedic surgery robot further research and development and clinical trials.
    Table 4 Partial financing in Beijing in July 2. Shanghai ophthalmology drug research and development manufacturer "Extreme Bio" completed a $32 million round of A-round financing this round of financing led by Morningside Ventures, the original incubation investment Nan Fung Life Sciences and Pivotal BioVenture Partners China continue to invest additional funds to gain more eye research pipelines and innovative product portfolios, and gradually develop the company's own research and development capabilities.
    Cell and gene therapy drug developers" and Yuan Shanghai "completed about 200 million yuan of Pre-C round financing, led by Yifeng Capital, Zhengsingu Innovation Capital, Pudong Science and Technology, ZhangjiangKe Investment, Jinpu Investment, Shengshan Assets, Jobe Ventures, Complex Investment, Fenghang Investment and other investment institutions to participate.
    This round of financing is mainly used for the company layout to start the construction of large-scale precision industrial park in Hong Kong, the introduction of overseas high-end talent, the development of gene therapy carrier new technology, new technology, etc. , which will further expand the company's leading position in the domestic gene therapy CRO/ CDMO segment.
    Precision medicine technology and product developer Dingjing Bio" completed a total of 120 million yuan of C-round financing, by the Chinese Academy of Sciences Joint Innovation Fund, Shenzhen Guoke Ruihua Equity Fund, Shanghai Inclusive Thai Venture Capital Fund and Zhuji by the creation of excellent equity fund and other institutions jointly invested.
    this round of funds will be used for the layout of third-party laboratory networks, in-body diagnostic reagents research and development and capacity upgrading, and continue to deepen the company's "service plus products" two-wheel drive business model.
    Table 5 Partial financing in Shanghai in July 3. Jiangsu pharmaceutical industry CRO and CMO service provider "Aussie Kang" completed the 450 million yuan B round of financing.
    the financing will be led by Zhongjin Jiatai (a fund owned by ZHONGC Capital) and Jinshi Investment, CCB International, Wenshi Investment and Shanghai Huaxu Investment.
    this round of financing will be mainly used for the construction of serum cell culture base Haimen base project and CDMO plate capacity expansion.
    Small molecule innovative drug research and development platform "Drug Jieankang" completed 60 million U.S. dollars of C-round financing, the current round of financing by The State Investment Investment, Haisong Medical - Nanjing Jiangbei Medical Innovation Fund, Guo Investment Ventures, Nanjing Fengling Capital, Enron Ventures, Eastern Handson investment, the original shareholder Jinpu Health Fund, Changjiang Guohong continued to increase its holdings.
    funds from this financing will be used to rapidly advance the global clinical development of core products, accelerate the process of commercialization and internationalization of the company, and continuously enrich the product pipeline.
    6 In July, some financing situation in Jiangsu province closed the first-tier market in the field of health care in July, and Beijing was the city with the largest amount and amount of financing.
    , the pharmaceutical sector is the sector with the largest amount of financing and the largest amount of financing, followed by the medical device sector.
    from a geographical perspective, financing projects are mainly concentrated in Beijing (19), Shanghai (18), Jiangsu (15), Guangdong (14) and Zhejiang (12), accounting for about 87% of the total number of financing projects.
    disclosed this month the largest capital increase in Baiji Shenzhou, the largest equity offering by a biotech company in the history of biopharmaceuticals worldwide.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.